World Investment Advisors Purchases 1,227 Shares of Cencora, Inc. (NYSE:COR)

World Investment Advisors lifted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 6.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,317 shares of the company's stock after purchasing an additional 1,227 shares during the period. World Investment Advisors' holdings in Cencora were worth $4,340,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. United Bank raised its holdings in shares of Cencora by 4.2% during the third quarter. United Bank now owns 5,601 shares of the company's stock valued at $1,261,000 after purchasing an additional 225 shares during the period. Public Sector Pension Investment Board increased its position in Cencora by 53.2% in the 3rd quarter. Public Sector Pension Investment Board now owns 6,908 shares of the company's stock valued at $1,555,000 after buying an additional 2,400 shares in the last quarter. Arete Wealth Advisors LLC raised its stake in Cencora by 4.9% during the 3rd quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company's stock worth $541,000 after buying an additional 113 shares during the period. Benjamin Edwards Inc. boosted its holdings in Cencora by 1,552.8% in the third quarter. Benjamin Edwards Inc. now owns 9,041 shares of the company's stock worth $2,035,000 after acquiring an additional 8,494 shares in the last quarter. Finally, Centiva Capital LP grew its stake in Cencora by 44.1% in the third quarter. Centiva Capital LP now owns 6,099 shares of the company's stock valued at $1,373,000 after acquiring an additional 1,866 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Cencora Stock Performance

Cencora stock traded down $0.86 during trading on Wednesday, hitting $273.87. The stock had a trading volume of 4,241,472 shares, compared to its average volume of 1,497,578. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The stock's 50 day moving average is $259.12 and its two-hundred day moving average is $244.21. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $296.65. The stock has a market cap of $53.11 billion, a price-to-earnings ratio of 38.96, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. Cencora's dividend payout ratio is currently 31.29%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Wells Fargo & Company upped their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a report on Friday, March 14th. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $280.20.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This represents a 21.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. The trade was a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock valued at $8,034,778 over the last three months. Company insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.